PAPER: Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab-DNA conjugates
Delivery of the anticancer drug Cetuximab to EGFR+ cancer cells has recently been reported in ChemBioChem.
The anticancer drug doxorubicin has low selectivity towards cancer cells. However, using the EGFR tageting antibody Cetuximab conjugated to ssDNA, doxorubicin delivery to EGFR+ cancer cells is achieved when the drug non-covalently intercalates to the DNA.